{"schema_version":"secwatch.filing_event.v1","accession":"0001140361-24-010088","form_type":"8-K","ticker":"ADMA","cik":"0001368514","company_name":"ADMA BIOLOGICS, INC.","filed_at":"2024-02-28T23:59:59+00:00","discovered_at":"2026-05-14T18:03:23.966934+00:00","generated_at":"2026-06-05T08:28:57.882390+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.78,"calibrated_materiality_score":0.78,"confidence":"high","headline":"ADMA Biologics Q4 rev $73.9M (+48%); FY rev $258.2M; raises FY24/25 guidance","bullets":["Q4 2023 total revenue $73.9M, up 48% YoY; FY 2023 total revenue $258.2M, up 68% YoY.","Q4 adjusted net income $8.5M (vs loss $12.2M); FY adjusted net income $0.7M (vs loss $59.2M).","FY 2024 guidance raised: revenue >$330M, net income >$65M, adjusted EBITDA >$90M.","FY 2025 guidance raised: revenue >$380M, net income >$115M, adjusted EBITDA >$140M.","Pipeline: S. pneumonia hyperimmune globulin potential peak rev $300-500M; ASCENIV pediatric study ongoing."],"urls":{"canonical":"https://secwatch.observer/filing/0001140361-24-010088","json":"https://secwatch.observer/filing/0001140361-24-010088.json","markdown":"https://secwatch.observer/filing/0001140361-24-010088.md","text":"https://secwatch.observer/filing/0001140361-24-010088.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1368514/000114036124010088/0001140361-24-010088-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1368514/000114036124010088/ef20022668_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-05T08:28:57.882390+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"0f06f37d3af365ad2cae15b87b0d2c103fb627f4","claim":"ADMA BIOLOGICS, INC. reported the full year 2023 and the three months ended December 31, 2023 results: revenue Total revenues were $73.9 million for the quarter ended December 31, 2023. Guidance raised.","evidence_excerpt":"ADMA Biologics, Inc. issued a press release announcing its financial results for the full year 2023 and the three months ended December 31, 2023","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1368514/000114036124010088/0001140361-24-010088-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the full year 2023 and the three months ended December 31, 2023"},{"label":"Revenue","value":"Total revenues were $73.9 million for the quarter ended December 31, 2023"},{"label":"Guidance","value":"raised"},{"label":"Result","value":"preliminary results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}